Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.19.2
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 11, 2015
Sep. 30, 2018
May 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Mar. 31, 2015
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2017
Clinical and Development Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             $ 7,100,000   $ 7,100,000        
Neupharma [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Payment of Upfront Fees           $ 1,000,000              
Reimbursement Of Cost Recognized As Revenue                 0 $ 31,000      
Neupharma [Member] | Additional Sales Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             40,000,000   40,000,000        
Neupharma [Member] | Clinical and Development Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             40,000,000   40,000,000        
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             22,500,000   22,500,000        
Dana-Farber [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Shares Issued, Price Per Share $ 0.065                        
Stock Issued During Period, Shares, Issued for Services 500,000       136,830                
Stock Issued During Period, Value, Issued for Services $ 32,500       $ 600,000                
Payment of Upfront Fees           1,000,000              
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 5.00%                        
Cash In Exchange For Common Stock $ 10,000,000                        
Payment For Non refundable Milestone payments   $ 1,000,000                      
Maintenance Fee                     $ 50,000    
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             28,600,000   28,600,000        
Maximum Potential Milestone Payments             21,500,000   21,500,000        
Dana-Farber [Member] | Additional Sales Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             60,000,000   60,000,000        
Maximum Potential Milestone Payments             60,000,000   60,000,000        
Dana-Farber [Member] | Commercial Sales In Specified Territories [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             21,500,000   21,500,000        
Teva Pharmaceutical Industries Ltd [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Payment of Upfront Fees       $ 500,000                  
Jubilant Biosys Ltd [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Payment of Upfront Fees                       $ 2,000,000  
Revenue Recognition, Milestone Method, Revenue Recognized             $ 13,000 $ 127,000 $ 24,000 394,000      
Research and Development Cost, Shared Percentage             50.00%   50.00%        
Non-Refundable Milestone Payment                         $ 400,000
Proceeds from Upfront Fees     $ 1,000,000                    
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             $ 89,000,000   $ 89,000,000        
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             59,500,000   59,500,000        
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             61,700,000   61,700,000        
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             89,000,000   89,000,000        
Maximum Potential Milestone Payments             89,000,000   89,000,000        
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             87,200,000   87,200,000        
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Maximum Potential Milestone Payments             4,800,000   4,800,000        
Collaboration Agreement With TGTX [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Payment of Upfront Fees           1,000,000              
Revenue Recognition, Milestone Method, Revenue Recognized             1,000,000 $ 0 1,400,000 $ 44,000      
Proceeds from Upfront Fees           $ 500,000              
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             7,000,000   7,000,000        
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             14,500,000   14,500,000        
Collaboration Agreement With TGTX [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             19,200,000   19,200,000        
Collaboration Agreement With TGTX [Member] | Clinical Development and Regulatory Milestones [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             9,400,000   9,400,000        
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]                          
Research and Development Arrangement, Contract to Perform for Others [Line Items]                          
Revenue Recognition Milestone Method, Payments Due             $ 25,500,000   $ 25,500,000